- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02406612
X-Seal EU Post-Market Clinical Follow-Up Protocol
January 30, 2018 updated by: Essential Medical, Inc.
X-Seal 6F Vascular Closure Device EU Post-Market Clinical Follow-Up Protocol
The study is designed to prospectively collect data on and confirm the safety and effectiveness of the X-Seal 6F Vascular Closure System in reducing time to hemostasis and time to ambulation for patients who have undergone diagnostic or interventional catheterization procedures using up to 6F sheaths when compared with standard compression techniques using data from literature surveys.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
47
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Lubeck, Germany
- University of Lubeck Hospital
-
Rostock, Germany
- University of Rostock Hosptial
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Candidate for non-emergent diagnostic or interventional cardiac catheterization via a femoral sheath ≤6F.
- Age ≥18 years.
- Understand and sign the study specific written informed consent form.
- In the investigator's opinion, the patient is suitable for the X-Seal vascular closure device, conventional hemostasis techniques and participation in an investigational trial.
- Eligible for sheath removal in the catheterization lab.
Exclusion Criteria:
- Patients who are known to be pregnant or lactating.
- Patients who are immunocompromised.
- Prior target artery closure with any vascular closure device or closure with manual compression win 30 days prior to this procedure.
- Patients with significant anemia (hemoglobin <10 g/DL, Hct<30).
- Patients who are morbidly obese or cachectic (BMI >40 or <20 kg/m2).
- Patients with Systolic Blood Pressure >180 mmHg, unless Systolic Pressure can be lowered by pharmacological agents prior to closure
- Patients who are currently participating in another clinical trial of an investigational drug or device that has not concluded the follow-up period.
- Patients with a baseline INR > 1.5 (e.g. coumadin therapy).
- Patients with a known bleeding disorder including thrombocytopenia (platelet count <100,000 cells/UL), thrombasthenia, hemophilia, or von Willebrand's disease.
- Patients with small femoral arteries (<4 mm), femoral artery stenosis resulting in a vessel diameter <4 mm, or patients with severe peripheral vascular disease.
- Patients with puncture site believed to be in the profunda femoris, superficial femoral artery, or at the bifurcation of the arteries.
- Common femoral artery with fluoroscopically visible calcium.
- Femoral arteries that are suspected to have experienced a back wall puncture or that underwent >one (1) arterial puncture during the catheterization procedure.
- Patients having a complication(s) at the femoral artery access site pre-sheath removal including hematoma, pseudoaneurysm, or arterio-venous fistula.
- Patients in whom continued heparin or other anticoagulant/antiplatelet therapy is planned (with the exception of Glycoprotein IIb/IIIa receptor blockers) following completion of the catheterization procedure.
- Patients whose ACT is >300 seconds prior to removal of the guiding catheter.
- Patients who cannot adhere to or complete the investigational protocol for any reason including but not limited to geographical residence or life threatening disease.
- Prior femoral vascular surgery or vascular graft in region of access site.
- Patient is unable to ambulate at baseline.
- Acute ST-elevation MI within 48 hours prior to procedure.
- Active systemic or cutaneous infection or inflammation
- Patients with unilateral or bilateral lower extremity amputation
- Patients with renal insufficiency (serum creatinine >2.5 mg/dl)
- Patients with marked tortuosity of the femoral or iliac artery
- Patients in whom bacterial contamination of the procedure sheath or surrounding tissues may have occurred as this may result in infection
- Patients in whom the puncture site is located above the most inferior border of the epigastric artery (IEA) and/or above the inguinal ligament based upon bony landmarks, since such a puncture site may result in a retroperitoneal hematoma/bleed. Perform a femoral angiogram to verify the location of the puncture site
- Patients with known allergies to beef products, collagen and/or collagen products, or polyglycolic or polylactic acid polymers
- Patients with known allergy to stainless steel or nickel. See MRI information in the IFU.
- Patients undergoing therapeutic thrombolysis
- Patients punctured through a vascular graft
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: X-Seal 6F Vascular Closure Device
The X-Seal 6F Vascular Closure device will be used to achieve hemostasis in both diagnostic and interventional procedures using up to a 6F procedure sheath.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major Complications
Time Frame: 30 days
|
The rate of major complications within approximately 30 days following the procedure.
|
30 days
|
Time-to-Hemostasis
Time Frame: Time to hemostasis will be measured as the time from removal of the guiding catheter to the time of cessation of common femoral artery bleeding, assessed up to 2 hours.
|
Time to hemostasis will be measured as the time from removal of the guiding catheter to the time of cessation of common femoral artery bleeding.
|
Time to hemostasis will be measured as the time from removal of the guiding catheter to the time of cessation of common femoral artery bleeding, assessed up to 2 hours.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time-to-Ambulation
Time Frame: Ambulation will be assessed 1.5 hours after removal of the access sheath for Diagnostic Patients, and 3 hours after procedure sheath removal for Interventional Patients.
|
The time from end of the procedure until the patient ambulates for the first time.
|
Ambulation will be assessed 1.5 hours after removal of the access sheath for Diagnostic Patients, and 3 hours after procedure sheath removal for Interventional Patients.
|
Adverse Events
Time Frame: 30 days
|
The rate of adverse events within approximately 30 days following the procedure.
All AEs counted, whether or not device-related.
|
30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2015
Primary Completion (Actual)
February 1, 2016
Study Completion (Actual)
June 1, 2016
Study Registration Dates
First Submitted
March 24, 2015
First Submitted That Met QC Criteria
March 30, 2015
First Posted (Estimate)
April 2, 2015
Study Record Updates
Last Update Posted (Actual)
October 29, 2018
Last Update Submitted That Met QC Criteria
January 30, 2018
Last Verified
January 1, 2018
More Information
Terms related to this study
Other Study ID Numbers
- PSD-028
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Femoral Arteriotomy Closure
-
Ladera MedicalAvaniaNot yet recruitingVascular Closure | Femoral Arteriotomy Closure
-
Essential Medical, Inc.CompletedFemoral Arteriotomy ClosureNetherlands, Italy
-
Essential Medical, Inc.TeleflexTerminated
-
Essential Medical, Inc.CompletedFemoral Arteriotomy ClosureUnited States, Canada
-
Essential Medical, Inc.Essential Medical LLC a subsidiary of Teleflex, IncorporatedRecruitingFemoral Arteriotomy ClosureUnited States
-
Essential Medical, Inc.CompletedFemoral Arteriotomy ClosureNetherlands, Denmark, Finland, Switzerland, Canada
-
Vivasure Medical LimitedCompletedPercutaneous Common Femoral Artery Arteriotomy ClosureGermany, United Kingdom, Ireland, Belgium
-
Vivasure Medical LimitedCompleted18 to 24 F Percutaneous Femoral Arteriotomy ClosureGermany
-
Medeon Biodesign, Inc.CompletedPercutaneous Closure of Arteriotomy in Common Femoral ArteryTaiwan, New Zealand, Australia
-
Vivasure Medical LimitedCompletedPercutaneous Closure of Arteriotomy in Common Femoral ArteryIreland
Clinical Trials on X-Seal 6F Vascular Closure Device
-
National Taiwan University HospitalRecruitingAortic Valve Stenosis | Transcatheter Aortic Valve ImplantationTaiwan
-
Cordis CorporationNAMSACompletedVenous Vascular ClosureUnited States
-
Erasmus Medical CenterCompletedAortic Valve StenosisNetherlands
-
University of FloridaAccess Pharmaceuticals, Inc.Completed
-
Essential Medical, Inc.CompletedFemoral Arteriotomy ClosureNetherlands, Italy
-
Essential Medical, Inc.TeleflexTerminated
-
Karolinska University HospitalUnknown
-
InSeal Medical Ltd.CompletedPercutaneous Closure of Artery Access SitesIsrael
-
InSeal Medical Ltd.TerminatedPercutaneous Closure of Artery Access SitesGermany
-
Zhuhai Tonbridge Medical Tech. Co., Ltd.Not yet recruitingHemostasis | Vascular Closure | Puncture | Femoral Artery | Endovascular ProcedureChina